Quarterly ResultMay 11, 2026, 04:33 PM
Cellectis Q1 Net Loss $17.8M; Positive Cema-cel Data; Key Trial Updates
AI Summary
Cellectis reported a Q1 2026 net loss of $17.8 million, a slight improvement from $18.1 million in Q1 2025, with revenues decreasing to $7.5 million. The company highlighted positive interim pivotal data from its partner Allogene for cema-cel (derived from Cellectis' UCART19), showing 58.3% MRD negativity in the ALPHA3 trial. Cellectis also anticipates key clinical milestones in Q4 2026, including interim Phase 2 data for lasme-cel and full Phase 1 data for eti-cel, and expects its cash runway to extend into Q4 2027. A legal dispute with Life Technologies Corporation regarding license agreements was also disclosed.
Key Highlights
- Q1 2026 net loss attributable to shareholders was $17.8 million ($0.18 per share).
- Q1 2026 revenues and other income decreased to $7.5 million from $12.0 million in Q1 2025.
- Cash, cash equivalents, and fixed-term deposits totaled $188 million as of March 31, 2026.
- Cash runway is projected to extend into Q4 2027.
- Allogene's cema-cel ALPHA3 trial showed 58.3% MRD negativity vs 16.7% in observation arm.
- First interim analysis for pivotal Phase 2 BALLI-01 trial (lasme-cel) expected in Q4 2026.
- Full Phase 1 dataset for NATHALI-01 trial (eti-cel) expected in Q4 2026.
- Life Technologies Corporation initiated arbitration regarding license agreement termination.